Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company Tolarex Ltd. has obtained a NIS 3.5 million grant from the Office of the Chief Scientist. Tolarex is developing an autoimmune therapy for graft versus host disease, in which the body rejects implants. Hadasit Bio is a subsidiary of Hadasit - the Technology Transfer Company of Hadassah Medical Organization . Published by Globes [online], Israel business news - www.globes-online.com - on February 21, 2010 © Copyright of Globes Publisher Itonut (1983) Ltd. 2010